Miniject, iStar Medical's micro-invasive glaucoma surgery (MIGS) device, has shown positive one-year results in its ‘Star II’ European trial.
One year after surgery, 29 patients with open-angle glaucoma had a mean intraocular pressure (IOP) of 15.1mmHg, corresponding to a 38% reduction from medicated baseline IOP, with 45% of them no longer requiring IOP-reducing medication at that point.
The implant, made of the porous ‘Star’ material developed by the University of Washington, USA, has demonstrated excellent bio-integration, allowing aqueous humor to flow freely through it. Studies conducted in rabbits – an animal model known for its aggressive inflammatory response – demonstrated that Miniject bio-integrated with surrounding tissue with no observed fibrosis, implant encapsulation, nor dense connective tissue obstructing drainage channels. Researchers say that this may result in the implant affording enduring IOP reduction.
